CN106581088A - Drug for treating coronary heart diseases - Google Patents
Drug for treating coronary heart diseases Download PDFInfo
- Publication number
- CN106581088A CN106581088A CN201611117422.2A CN201611117422A CN106581088A CN 106581088 A CN106581088 A CN 106581088A CN 201611117422 A CN201611117422 A CN 201611117422A CN 106581088 A CN106581088 A CN 106581088A
- Authority
- CN
- China
- Prior art keywords
- parts
- coronary heart
- medicine
- heart disease
- crospovidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug for treating coronary heart diseases. The drug for treating the coronary heart diseases is prepared from, by weight, 8-19 parts of procaine hydrochloride, 17-25 parts of cannabinoid A, 5-10 parts of ginkgo biloba extracts, 2-6 parts of 5-isosorbide mononitrate, 11-18 parts of aspirin, 1.5-1.8 parts of heparin, 0.5-1.9 parts of crospovidone, 8-15 parts of algal polysaccharides and 2-4 parts of 3-ethyl-(4-aminophenyl)-dioxopiperidine. The prepared drug can rapidly cure the myocardial ischemia type and myocardial infarction type coronary heart diseases, the curative effect is remarkable, and the coronary heart diseases do not relapse in a long time after being cured.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of medicine for treating coronary heart disease.
Background technology
Coronary heart disease is the primary killers of human health, and with the acceleration of globalization process, cardiovascular and cerebrovascular diseases are in development
Middle country begins to extend, and becomes the cause of death of No. 1 in the world.The World Health Organization is classified as follows to coronary heart disease：(1) without disease
Shape myocardial ischemia type：Silent myocardial ischemia or invisible myocardial ischemia are called, refer to the objective evidence (heart for truly having myocardial ischemia
Electrical activity, left chamber function, Myocardial Perfusion and myocardial metabolism etc. are abnormal), but lack pectoralgia or the master related to myocardial ischemia
See symptom.(2) angina pectoris：Refer to by coronary insufficiency, cardiac muscle drastically, ischemia and caused by anoxic sending out
The property made pectoralgia or the uncomfortable one group of clinical syndrome for main performance of chest.(3) miocardial infarction (dead) type：Refer to that coronary artery goes out
Existing AP or on this basis thrombosis, cause blood flow coronarius drastically to reduce or interrupt, and make corresponding
There is seriously and enduringly acute ischemia in cardiac muscle, ultimately results in the ischemic necrosis of cardiac muscle, belongs to the serious types of coronary heart disease.(4)
Ischemic cardiomyopathy type：Refer to because long-term myocardial ischemia causes myocardium limitation or diffuse fibrousization, so as to produce heart
Shrink and (or) diastolic function is impaired, cause a series of clinics such as Heart enlargement or stiff, congestive heart failure, arrhythmia cordis
The clinical syndrome of performance.(5) sudden death type：It is now recognized that patient's heart arrest is athero- hard in coronary artery
On the basis of change, coronarospasm or microcirculation embolism occur causes Acute myocardial ischemia, causes local electro physiology disorderly, draws
Caused by playing temporary transient severe arrhythmia (particularly ventricular fibrillation).
The treatment of coronary heart disease includes rehabilitation of drug therapy, PCI and surgical intervention, coronary heart disease etc., but total
For, also undesirable for the therapeutic effect of coronary heart disease at present, especially with treatment by Chinese herbs, cycle length simultaneously can recur often,
And side effect is obvious.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating coronary heart disease, to solve above-mentioned background technology in propose ask
Topic.
For achieving the above object, the present invention provides following technical scheme：
A kind of medicine for treating coronary heart disease, be according to the primary raw material of weight portion：Procaine hydrochloride 8-19 parts, cannboid
A17-25 parts, Bilobanoate 5-10 parts, 5- Isosorbide Mononitrate 2-6 parts, aspirin 11-18 parts, heparin 1.5-1.8 parts,
Crospovidone 0.5-1.9 parts, algal polysaccharides 8-15 parts, 3- ethyls-(4- aminophenyls)-piperidine dione 2-4 parts.
As further scheme of the invention：The medicine of the treatment coronary heart disease, be according to the primary raw material of weight portion：Salt
Sour procaine 11-18 parts, cannboid A 19-22 parts, Bilobanoate 8-10 parts, 5- Isosorbide Mononitrate 2-6 parts, Ah Si
Woods 14-17 parts, heparin 1.5-1.8 parts, Crospovidone 0.8-1.3 parts, algal polysaccharides 10-12 parts, 3- ethyls-(4- aminobenzenes
Base)-piperidine dione 2-4 parts.
As further scheme of the invention：The medicine of the treatment coronary heart disease, be according to the primary raw material of weight portion：Salt
15 parts of sour procaine, 21 parts of cannboid A, 9 parts of Bilobanoate, 4 parts of 5- Isosorbide Mononitrates, 16 parts of aspirin, heparin
1.7 parts, 1.2 parts of Crospovidone, 11 parts of algal polysaccharides, 3- ethyls -3 parts of (4- aminophenyls)-piperidine dione.
A kind of preparation method of the medicine for treating coronary heart disease, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh procaine hydrochloride, cannboid A, Bilobanoate,
5- Isosorbide Mononitrates, aspirin, heparin, Crospovidone, algal polysaccharides, 3- ethyls-(4- aminophenyls)-piperidines two
Ketone, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4-8min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 4-8 DEG C, packaging obtains final product the medicine for the treatment of coronary heart disease to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine prepared by the present invention can quickly eliminate myocardial ischemia type and myocardial infarction type coronary heart disease, evident in efficacy, and more
Do not recur for a long time afterwards.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of medicine for treating coronary heart disease, be according to the primary raw material of weight portion：8 parts of procaine hydrochloride, cannboid A
17 parts, 5 parts of Bilobanoate, 2 parts of 5- Isosorbide Mononitrates, 11 parts of aspirin, 1.5 parts of heparin, 0.5 part of Crospovidone, sea
8 parts of polysaccharides, 3- ethyls -2 parts of (4- aminophenyls)-piperidine dione.
A kind of preparation method of the medicine for treating coronary heart disease, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh procaine hydrochloride, cannboid A, Bilobanoate,
5- Isosorbide Mononitrates, aspirin, heparin, Crospovidone, algal polysaccharides, 3- ethyls-(4- aminophenyls)-piperidines two
Ketone, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4min, controls RSD≤5%, presses after mixing
Piece and low temperature drying, at 4 DEG C, packaging obtains final product the medicine for the treatment of coronary heart disease to temperature control.
Embodiment 2
A kind of medicine for treating coronary heart disease, be according to the primary raw material of weight portion：11 parts of procaine hydrochloride, cannboid A
19 parts, 8 parts of Bilobanoate, 2 parts of 5- Isosorbide Mononitrates, 14 parts of aspirin, 1.5 parts of heparin, 0.8 part of Crospovidone, sea
10 parts of polysaccharides, 3- ethyls -2 parts of (4- aminophenyls)-piperidine dione.
A kind of preparation method of the medicine for treating coronary heart disease, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh procaine hydrochloride, cannboid A, Bilobanoate,
5- Isosorbide Mononitrates, aspirin, heparin, Crospovidone, algal polysaccharides, 3- ethyls-(4- aminophenyls)-piperidines two
Ketone, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4min, controls RSD≤5%, presses after mixing
Piece and low temperature drying, at 4 DEG C, packaging obtains final product the medicine for the treatment of coronary heart disease to temperature control.
Embodiment 3
A kind of medicine for treating coronary heart disease, be according to the primary raw material of weight portion：15 parts of procaine hydrochloride, cannboid A
21 parts, 9 parts of Bilobanoate, 4 parts of 5- Isosorbide Mononitrates, 16 parts of aspirin, 1.7 parts of heparin, 1.2 parts of Crospovidone, sea
11 parts of polysaccharides, 3- ethyls -3 parts of (4- aminophenyls)-piperidine dione.
A kind of preparation method of the medicine for treating coronary heart disease, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh procaine hydrochloride, cannboid A, Bilobanoate,
5- Isosorbide Mononitrates, aspirin, heparin, Crospovidone, algal polysaccharides, 3- ethyls-(4- aminophenyls)-piperidines two
Ketone, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 6min, controls RSD≤5%, presses after mixing
Piece and low temperature drying, at 6 DEG C, packaging obtains final product the medicine for the treatment of coronary heart disease to temperature control.
Embodiment 4
A kind of medicine for treating coronary heart disease, be according to the primary raw material of weight portion：18 parts of procaine hydrochloride, cannboid A
22 parts, 10 parts of Bilobanoate, 6 parts of 5- Isosorbide Mononitrates, 17 parts of aspirin, 1.8 parts of heparin, 1.3 parts of Crospovidone, sea
12 parts of polysaccharides, 3- ethyls -4 parts of (4- aminophenyls)-piperidine dione.
A kind of preparation method of the medicine for treating coronary heart disease, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh procaine hydrochloride, cannboid A, Bilobanoate,
5- Isosorbide Mononitrates, aspirin, heparin, Crospovidone, algal polysaccharides, 3- ethyls-(4- aminophenyls)-piperidines two
Ketone, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 8min, controls RSD≤5%, presses after mixing
Piece and low temperature drying, at 8 DEG C, packaging obtains final product the medicine for the treatment of coronary heart disease to temperature control.
Embodiment 5
A kind of medicine for treating coronary heart disease, be according to the primary raw material of weight portion：19 parts of procaine hydrochloride, cannboid A
25 parts, 10 parts of Bilobanoate, 6 parts of 5- Isosorbide Mononitrates, 18 parts of aspirin, 1.8 parts of heparin, 1.9 parts of Crospovidone, sea
15 parts of polysaccharides, 3- ethyls -4 parts of (4- aminophenyls)-piperidine dione.
A kind of preparation method of the medicine for treating coronary heart disease, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh procaine hydrochloride, cannboid A, Bilobanoate,
5- Isosorbide Mononitrates, aspirin, heparin, Crospovidone, algal polysaccharides, 3- ethyls-(4- aminophenyls)-piperidines two
Ketone, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 8min, controls RSD≤5%, presses after mixing
Piece and low temperature drying, at 8 DEG C, packaging obtains final product the medicine for the treatment of coronary heart disease to temperature control.
Pharmacological evaluation is as follows：
Creatine kinase (CK), aspartate amino transferase (AST) and lactic dehydrogenase (LDH) are to be present in cardiac muscle carefully
The protease of intracellular, when cellular damage or necrosis, CK, AST, LDH just can be discharged in blood from intracellular, therefore determine blood
Clear CK, AST, LDH can be used as the indexs of reflecting myocardium degree of necrosis.
From the embodiment of the present invention 3 prepare medicine as medicine for treatment.
(1) high fat feeding and isoprel cause chronic myocardial ischemia model
SD rats are randomly divided into 3 groups (normal group, model group, treatment groups) by body weight, 20 per group, male and female half and half.Modeling
After success, rat is administered each group, and normal group administration is physiological saline, and model group administration is physiological saline, and treatment group is to control
Treat medication water-soluble liquid, gavage consumption be 1ml, daily gavage three times, laggard row vein takes hematometry AST, CK, LDH within 7 days.
As a result as follows, the CK (U/L) of normal group is that 394 ± 25, AST is 62 ± 11, LDH (U/L) 447 ± 39；Model group
CK (U/L) be 1354 ± 241, AST be 187 ± 18, LDH (U/L) 1589 ± 366；The CK (U/L) for the treatment of group is 496 ± 71,
AST is 75 ± 9, LDH (U/L) 662 ± 141；CK, AST, LDH level of model group rats significantly increases compared with normal group, after administration
CK, AST, LDH level of rat is significantly reduced, and there is significant difference (P ＜ 0.05) in treatment group compared with model group, illustrates right
Myocardial infarction and ischemia model rat has significant therapeutic action.
(2) myocardial infarction model
From body weight 240-260g male SD rat, reserve 20 rats as normal group outside, remaining rats by intraperitoneal injection
30mg/kg anaesthetized with pentobarbital rats.Back of the body position is fixed, and ball (size is just enclosed within rat head) is inhaled with more than half, with ALC-V8
Type animal respirator, tidal volume 10ml/kg, 45～50 times/min of respiratory rate, respiratory quotient is 1: 1.Chest unhairing, sterilization, edge
The longitudinally slit skin 20mm of left mid-clavicular line, in the 4th, 5 intercostal blunt separation muscle layer, with curved hemostat intercostal muscle and pleura is strutted
Into thoracic cavity, pericardium is cut off, with middle finger right side chest corridor is gently pressed, heart is extruded, in left auricle of heart and pulmonary artery in thumb pressure xiphoid-process bottom
With great cardiac vein as mark between circular cone, 2～3mm passes through the left front drop of coronary artery with 6-0 hurtless measures suture under left auricle of heart root
, depth of needle about 0.5mm ligatures ramus descendens anterior arteriae coronariae sinistrae.Heart is sent back in thoracic cavity, thoracic cavity is gently extruded, chest is excluded
Cavity space gas, layer-by-layer suture thoracic incision closes chest.The prevention infection in three days of postoperative intramuscular injection penicillin.After modeling success, 3 are randomly divided into
Group (normal group, model group, treatment group), rat is administered each group, and normal group administration is physiological saline, and model group administration is made a living
Reason salt solution, treatment group for medicine for treatment water-soluble liquid, gavage consumption be 1ml, daily gavage three times, laggard row vein takes within 7 days
Hematometry AST, CK, LDH.
As a result as follows, the CK (U/L) of normal group is that 365 ± 57, AST is 68 ± 10, LDH (U/L) 416 ± 33；Model group
CK (U/L) be 1496 ± 185, AST be 198 ± 24, LDH (U/L) 1489 ± 297；The CK (U/L) for the treatment of group is 463 ± 40,
AST is 72 ± 11, LDH (U/L) 549 ± 91；CK, AST, LDH level of model group rats significantly increases compared with normal group, after administration
CK, AST, LDH level of rat is significantly reduced, and there is significant difference (P ＜ 0.05) in treatment group compared with model group, illustrates right
Myocardial infarction type rat model has significant therapeutic action.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. a kind of medicine for treating coronary heart disease, it is characterised in that the primary raw material according to weight portion is：Procaine hydrochloride 8-19
Part, cannboid A 17-25 parts, Bilobanoate 5-10 parts, 5- Isosorbide Mononitrate 2-6 parts, aspirin 11-18 parts, heparin
1.5-1.8 parts, Crospovidone 0.5-1.9 parts, algal polysaccharides 8-15 parts, 3- ethyls-(4- aminophenyls)-piperidine dione 2-4 parts.
2. it is according to claim 1 treatment coronary heart disease medicine, it is characterised in that the medicine of the treatment coronary heart disease, press
It is according to the primary raw material of weight portion：Procaine hydrochloride 11-18 parts, cannboid A 19-22 parts, Bilobanoate 8-10 parts, 5- are mono-
ISDN 2-6 parts, aspirin 14-17 parts, heparin 1.5-1.8 parts, Crospovidone 0.8-1.3 parts, algal polysaccharides 10-
12 parts, 3- ethyls-(4- aminophenyls)-piperidine dione 2-4 parts.
3. it is according to claim 1 and 2 treatment coronary heart disease medicine, it is characterised in that the medicine of the treatment coronary heart disease,
Primary raw material according to weight portion is：15 parts of procaine hydrochloride, 21 parts of cannboid A, 9 parts of Bilobanoate, the different mountain of 5- single nitric acids
4 parts of pear ester, 16 parts of aspirin, 1.7 parts of heparin, 1.2 parts of Crospovidone, 11 parts of algal polysaccharides, 3- ethyls-(4- aminobenzenes
Base) 3 parts of-piperidine dione.
4. a kind of preparation method of the medicine of the treatment coronary heart disease as described in claim 1-3 is arbitrary, it is characterised in that concrete step
Suddenly it is：
First, in pharmaceutical grade clean area, procaine hydrochloride, cannboid A, Bilobanoate, 5- are weighed by above-mentioned metering ratio mono-
ISDN, aspirin, heparin, Crospovidone, algal polysaccharides, 3- ethyls-(4- aminophenyls)-piperidine dione, mistake
Sieve, machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, and compressing tablet is simultaneously after mixing
Low temperature drying, at 4-8 DEG C, packaging obtains final product the medicine for the treatment of coronary heart disease to temperature control.
5. it is according to claim 4 treatment coronary heart disease medicine preparation method, it is characterised in that in concrete steps mix
6min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611117422.2A CN106581088A (en) | 2016-12-07 | 2016-12-07 | Drug for treating coronary heart diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611117422.2A CN106581088A (en) | 2016-12-07 | 2016-12-07 | Drug for treating coronary heart diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581088A true CN106581088A (en) | 2017-04-26 |
Family
ID=58596609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611117422.2A Pending CN106581088A (en) | 2016-12-07 | 2016-12-07 | Drug for treating coronary heart diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581088A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113575584A (en) * | 2021-08-12 | 2021-11-02 | 山东森达奥农业科技研究院有限公司 | Agricultural synergistic marine active matter and preparation method and application thereof |
| WO2023108277A1 (en) * | 2021-12-14 | 2023-06-22 | Agile Pharmaceuticals Solutions Inc. | Cannabinoid and psychedelic formulations comprising hydrotropic agents |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285017A (en) * | 2013-05-22 | 2013-09-11 | 刘光权 | Compound isosorbide mononitrate aspirin sustained-release capsule preparation and preparation method |
-
2016
- 2016-12-07 CN CN201611117422.2A patent/CN106581088A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285017A (en) * | 2013-05-22 | 2013-09-11 | 刘光权 | Compound isosorbide mononitrate aspirin sustained-release capsule preparation and preparation method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113575584A (en) * | 2021-08-12 | 2021-11-02 | 山东森达奥农业科技研究院有限公司 | Agricultural synergistic marine active matter and preparation method and application thereof |
| WO2023108277A1 (en) * | 2021-12-14 | 2023-06-22 | Agile Pharmaceuticals Solutions Inc. | Cannabinoid and psychedelic formulations comprising hydrotropic agents |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101424335B1 (en) | Healthy and functional food for the improvement of blood flow | |
| US20170128514A1 (en) | Pharmaceutical composition for treating cardio-cerebrovascular diseases and method for preparing the same | |
| CN106581088A (en) | Drug for treating coronary heart diseases | |
| CN110339204A (en) | A kind of composition containing folic acid and its preparing the application in cerebral apoplexy drug | |
| CN106727744A (en) | One kind treats anginal medicine | |
| CN104544050A (en) | Method for producing special diet food rich in peanut peptides for patients with hypertension | |
| CN106619701A (en) | Western medicine composition for treating coronary heart disease and preparation method thereof | |
| CN108066712A (en) | A kind of benefiting qi and nourishing blood Chinese medicine composition | |
| CN107158008A (en) | A kind of pharmaceutical composition for treating myocardial infarction | |
| CN106729675A (en) | It is a kind of to treat pharmaceutical composition of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN104055909A (en) | Application of compound donkey-hide gelatin pulp in preparation of medicament for menstrual period health care | |
| CN106727505A (en) | A kind of Western medicine combination for treating coronary heart disease and preparation method thereof | |
| RU2468812C2 (en) | Agent possessing adaptogenic, tonic and general tonic action, and method for preparing it | |
| CN104490883B (en) | It is a kind of to treat pharmaceutical composition of cardiovascular and cerebrovascular disease and its production and use | |
| RU2341279C2 (en) | Filmed tablet containing red grape leaves extract | |
| CN106389492A (en) | Chinese and western medicine composition for treating hypertension and preparing method and application thereof | |
| CN106729518A (en) | A kind of tea beverage of hypotensive and preparation method and application | |
| CN111166774A (en) | Composition for preventing and treating cerebral ischemia diseases and application thereof | |
| WO2018145364A1 (en) | Use of 3,4,7-trihydroxyisoflavone or 3-methoxy daidzein in preparation of medicaments for inhibiting platelet aggregation and thrombosis | |
| CN104189288B (en) | A kind of Chinese medicine composition for treating myocardial infarction and its application | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN103316217A (en) | Traditional Chinese medicine preparation for treating heart diseases and preparation method therefor | |
| CN105963292B (en) | A kind of pharmaceutical composition and its application for myocardial infarction treatment | |
| CN104352671A (en) | Novel medical application of traditional Chinese medicine composition | |
| CN109172815B (en) | Application of the human urokinase-type peptidase in preparation treatment hypertension complicated with hyperlipemia drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |